Vycor Medical, Inc.
VYCO
$0.0648
-$0.0041-5.95%
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | 1.31% | -4.56% | 13.10% | 19.43% | 16.18% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.31% | -4.56% | 13.10% | 19.43% | 16.18% |
| Cost of Revenue | 7.78% | -2.33% | 9.41% | 2.99% | 3.55% |
| Gross Profit | 0.61% | -4.82% | 13.55% | 21.57% | 17.75% |
| SG&A Expenses | 10.18% | -2.20% | -5.91% | -10.17% | -14.96% |
| Depreciation & Amortization | 2.60% | 1.38% | 0.17% | -1.03% | -4.95% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 8.81% | -2.14% | -3.45% | -7.13% | -12.11% |
| Operating Income | -811.54% | -67.47% | 98.82% | 113.08% | 103.43% |
| Income Before Tax | -113.82% | -21.50% | 68.21% | 84.21% | 81.06% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -113.82% | -21.50% | 68.21% | 84.21% | 81.06% |
| Earnings from Discontinued Operations | 23.81% | 42.86% | -15.38% | -24.53% | 25.00% |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -107.84% | -18.97% | 66.85% | 82.79% | 80.42% |
| EBIT | -811.54% | -67.47% | 98.82% | 113.08% | 103.43% |
| EBITDA | -141.08% | -282.05% | 136.68% | 141.17% | 123.45% |
| EPS Basic | -22.48% | -4.67% | 34.16% | 47.19% | 49.61% |
| Normalized Basic EPS | -111.76% | -20.69% | 69.35% | 84.62% | 81.91% |
| EPS Diluted | -19.70% | -2.61% | 32.67% | 45.89% | 48.44% |
| Normalized Diluted EPS | -89.47% | -12.90% | 66.13% | 82.05% | 79.79% |
| Average Basic Shares Outstanding | 0.36% | 0.64% | 1.55% | 2.83% | 4.22% |
| Average Diluted Shares Outstanding | -3.23% | -2.98% | 5.31% | 6.65% | 8.09% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
